Fastenal Company (NASDAQ:FAST) Chief Executive Officer Willard D. Oberton has notified the Board of Directors he intends to resign his CEO post effective December 31. The Board of the industrial and construction supply company modified the positions and duties of Leland J. Hein, Jr. by electing him as Chief Executive Officer effective January 1, 2015, in addition to his role as President. Hein joined the Company in 1985 and has held various sales and managerial roles, serving as a General Manager, District Manager, Regional Vice President, Executive Vice President-Sales, and President , a position he has held since July 2012. Oberton will continue to serve as Chairman of the Board. Shares of Fastenal Company (NASDAQ:FAST) are at $44.91 within a 52-week range of $40.18 - $52.21.Enerplus Corp (USA) (NYSE:ERF) Friday reported a profitable quarter in Q3 ended September 30, driven by stronger production results. The North American oil and gas explorer earned C$67.4 million, or C$0.33 per share, recovering from a net loss of C$3.7 million, or C$0.02 per share, it reported in the same period last year. The Street's call was only for C$0.27, according to Capital IQ. Funds flow from operations were C$212.8 million, or C$1.04 per share, up from last year's C$196.2 million, or C$0.98 per share.During the quarter, Enerplus Corp (USA) (NYSE:ERF) produced an average of 104,035 BOE/day versus 87,729 BOE/day in 2013. As a result, it is increasing the low end of its previously announced 2014 production guidance range by 2,000 BOE per day and now expect full year production to average between 102,000 - 104,000 BOE per day. Its preliminary plans for 2015 target continued production growth of 5 - 10% per share with a modestly lower capital spending program than in 2014, it added. ERF has a 52-week range of $12.67 - $25.37.Fibrocell Science Inc (NASDAQ:FCSC) on Friday reported weaker-than-expected quarterly losses as the company focused on advancing a new drug to treat recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder. For Q3, the cell therapy treatment company reported a net loss of $0.15 per share, compared to a loss of $0.24 per share for the same period in 2013. Revenues for each of the third quarters of 2014 and 2013 were insignificant. Analysts expected a net loss per share of $0.14, according to Capital IQ estimates.Research and development expenses in the quarter were $2.9 million, as compared with $8.7 million last year. The decrease in R&D expenses was due to $6.4 million in stock issuance costs for the company's collaboration with Intrexon in Q3 2013, offset by increased costs of $0.6 million related to Fibrocell's RDEB pre-clinical study. Fibrocell Science Inc (NASDAQ:FCSC) said it is on track to file an investigational new drug application (IND) with the U.S. Food and Drug Administration for GM-HDF-COL7 in the first half of 2015. FCSC shares fell a penny to $2.66 early Friday, approaching the stock's 52-week low of $2.60.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
